Direct intervention of incretin to protect the blood-retinal barrier - Suppression on onset and progression of diabetic retinopathy -
| Project/Area Number |
25460654
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Applied pharmacology
|
|---|
| Research Institution | Gifu Pharmaceutical University |
|---|
Principal Investigator |
ADACHI TETSUO 岐阜薬科大学, 薬学部, 教授 (40137063)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HARA Hirokazu 岐阜薬科大学, 薬学部, 准教授 (30305495)
KAMIYA Tetsuro 岐阜薬科大学, 薬学部, 助教 (60453057)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
IKEDA Tsunehiko 大阪医科大学, 医学部, 教授 (70222891)
|
|---|
| Research Collaborator |
YASUDA Hiroyuki
MAKINO Junya
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 糖尿病 / エピジェネティクス / ストレス / インクレチン / 抗酸化酵素 / 血管内皮細胞 / シグナル伝達 |
|---|
| Outline of Final Research Achievements |
Exendin-4 is an analog of the glucagon-like peptide 1 (GLP-1) and is used in the treatment of type 2 diabetes. Since human GLP-1 receptor has been identified in various cells besides pancreatic cells, exendin-4 is expected to exert extrapancreatic actions. The expression of extracellular-superoxide dismutase (EC-SOD), a major SOD isozyme that is crucially involved in redox homeostasis, is regulated by epigenetic factors. We demonstrated that exendin-4 induced the expression of EC-SOD in A549 human lung adenocarcinoma epithelial cell line and human retinal microvascular endothelial cells through demethylation of some methyl-CpG sites and histone H3 acetylation at the EC-SOD proximal promoter region, respectively. Moreover, plasma EC-SOD concentrations in diabetic patients were elevated by incretin-based therapies. Therefore, incretin-based therapies may exert direct extrapancreatic effects in order to protect blood vessels by enhancing anti-oxidative activity.
|
Report
(4 results)
Research Products
(33 results)
-
-
-
-
-
-
[Journal Article] Foresight of physical development indicated by the national health and nutrition survey in Japan: An approach in terms of biomedical sciences2015
Author(s)
Maehata Y, Miyamoto C, Tsukinoki T, Takahashi S, Yoshino F, Wada-Takahashi S, Yoshida A, Tanaka A, Adachi T, Igoshi N, Shiba T, Kishikawa N, Imazato T, Suzuki I, Ihara H, Shumonura H, Okabe H, Yanagisaawa T, Hosho A, Maehata E
-
Journal Title
Int. J. Anal. Bio-Sci.
Volume: 3
Pages: 63-72
Related Report
Peer Reviewed
-
-
-
[Journal Article] Plasma levels of nitric oxide metabolites are markedly reduced in normotensive men with electrocardiographically determined left ventricular hypertrophy2014
Author(s)
Kamezaki F, Tsutsui M, Takahashi M, Sonoda S, Kubo T, Fujino Y, Adachi T, Abe H, Takeuchi M, Mayumi T, Otsuji Y
-
Journal Title
Hypertension
Volume: 64
Issue: 3
Pages: 516-522
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] EC-SOD levels in pre-dialysis sera and the relationship with HOMA-R2014
Author(s)
Maehata Y, Maehata K, Adachi T, Tanaka A, Ikoshi N, Kuroda N, Kishikawa N, Shiba T, Matsushita M, Yanagisawa T, Maehata E, Shimomura H
-
Journal Title
Int. J. Anal. Bio-Sci.
Volume: 2
Pages: 155-162
NAID
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
